Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618368 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ABRD4CYP2C9 | |
| SCHEMBL2602437 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ACYP2C19RXFP1 | |
| SCHEMBL2607666 | 0.84 | CYP1A2 (0.48) | ALDH1A1MEN1KMT2AAKT1CYP2C9 | |
| SCHEMBL10018495 | 0.83 | TP53 (0.61) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2618367 | 0.82 | KDM4E (0.44) | ALDH1A1MEN1KMT2ABRD4CYP2C9 | |
| SCHEMBL9792190 | 0.80 | BRD4 (0.52) | ALDH1A1MEN1KMT2ABRD4AKT1 | |
| SCHEMBL5487635 | 0.79 | HTT (0.45) | ALDH1A1MEN1KMT2AAKT1CYP2C19 | |
| SCHEMBL3439910 | 0.78 | BRD4 (0.49) | ALDH1A1MEN1KMT2ABRD4 | |
| SCHEMBL3439909 | 0.78 | TP53 (0.46) | ALDH1A1MEN1KMT2ABRD4CYP2C19 | |
| SCHEMBL2618363 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AAKT1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334302-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | ALDH1A1 996/4885MEN1 2838/4885KMT2A 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.